Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | ST6GALNAC5 | Human | (+)-catechin | multiple interactions | EXP | | 6480464 | [Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:24763279 | ST6GALNAC5 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:22079256 | ST6GALNAC5 | Human | 1,2-dichloroethane | decreases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | ethylene dichloride results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:28960355 | ST6GALNAC5 | Human | 17beta-estradiol | decreases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | Estradiol results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:19484750 | ST6GALNAC5 | Human | 4,4'-diaminodiphenylmethane | increases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | 4 and 4'-diaminodiphenylmethane results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:18648102 | ST6GALNAC5 | Human | 4-hydroxyphenyl retinamide | decreases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:28973697 | ST6GALNAC5 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | Fenretinide results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:28973697 | ST6GALNAC5 | Human | 6-propyl-2-thiouracil | increases expression | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Propylthiouracil results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:24780913 and PMID:25825206 | ST6GALNAC5 | Human | acrylamide | decreases expression | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Acrylamide results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:28959563 | ST6GALNAC5 | Human | acrylamide | decreases expression | EXP | | 6480464 | Acrylamide results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:32763439 | ST6GALNAC5 | Human | Aflatoxin B2 alpha | increases methylation | EXP | | 6480464 | aflatoxin B2 results in increased methylation of ST6GALNAC5 intron | CTD | PMID:30157460 | ST6GALNAC5 | Human | all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:18052213 | ST6GALNAC5 | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:21934132 and PMID:23724009 | ST6GALNAC5 | Human | arsane | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of ST6GALNAC5 gene | CTD | PMID:25304211 | ST6GALNAC5 | Human | arsenic atom | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of ST6GALNAC5 gene | CTD | PMID:25304211 | ST6GALNAC5 | Human | arsenite(3-) | increases methylation | EXP | | 6480464 | arsenite results in increased methylation of ST6GALNAC5 promoter | CTD | PMID:23974009 | ST6GALNAC5 | Human | atrazine | affects methylation | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Atrazine affects the methylation of ST6GALNAC5 gene | CTD | PMID:35440735 | ST6GALNAC5 | Human | benzene | decreases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | Benzene results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:15120971 and PMID:15122651 | ST6GALNAC5 | Human | benzo[a]pyrene | increases expression | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Benzo(a)pyrene results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:21839799 | ST6GALNAC5 | Human | benzo[a]pyrene | increases methylation | EXP | | 6480464 | Benzo(a)pyrene results in increased methylation of ST6GALNAC5 3' UTR more ... | CTD | PMID:27901495 | ST6GALNAC5 | Human | bisphenol A | decreases expression | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:25181051 | ST6GALNAC5 | Human | bisphenol A | decreases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | bisphenol A results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:32156529 | ST6GALNAC5 | Human | bisphenol A | increases expression | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:34947998 | ST6GALNAC5 | Human | bisphenol A | increases methylation | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | bisphenol A results in increased methylation of ST6GALNAC5 gene | CTD | PMID:28505145 | ST6GALNAC5 | Human | carbamazepine | affects expression | EXP | | 6480464 | Carbamazepine affects the expression of ST6GALNAC5 mRNA | CTD | PMID:25979313 | ST6GALNAC5 | Human | carbon nanotube | increases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:25554681 | ST6GALNAC5 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to ST6GALNAC5 gene] | CTD | PMID:28238834 | ST6GALNAC5 | Human | Cuprizon | increases expression | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Cuprizone results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:27523638 | ST6GALNAC5 | Human | DDE | decreases expression | EXP | | 6480464 | Dichlorodiphenyl Dichloroethylene results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:38568856 | ST6GALNAC5 | Human | Didecyldimethylammonium | decreases expression | EXP | | 6480464 | didecyldimethylammonium results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:32763356 | ST6GALNAC5 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ST6GALNAC5 | Human | entinostat | decreases expression | EXP | | 6480464 | entinostat results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:26272509 | ST6GALNAC5 | Human | entinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:27188386 | ST6GALNAC5 | Human | ethanol | affects expression | ISO | St6galnac5 (Mus musculus) | 6480464 | Ethanol affects the expression of ST6GALNAC5 mRNA | CTD | PMID:30319688 | ST6GALNAC5 | Human | folic acid | decreases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | Folic Acid results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:25629700 | ST6GALNAC5 | Human | fonofos | increases methylation | EXP | | 6480464 | Fonofos results in increased methylation of ST6GALNAC5 promoter | CTD | PMID:22847954 | ST6GALNAC5 | Human | formaldehyde | decreases expression | EXP | | 6480464 | Formaldehyde results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:20655997 | ST6GALNAC5 | Human | genistein | decreases expression | ISO | St6galnac5 (Mus musculus) | 6480464 | Genistein results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:32186404 | ST6GALNAC5 | Human | glyphosate | increases methylation | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Glyphosate results in increased methylation of ST6GALNAC5 gene | CTD | PMID:31011160 | ST6GALNAC5 | Human | glyphosate | affects methylation | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Glyphosate affects the methylation of ST6GALNAC5 gene | CTD | PMID:35440735 | ST6GALNAC5 | Human | hydroquinone | decreases expression | EXP | | 6480464 | hydroquinone results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:31256213 | ST6GALNAC5 | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:35811015 | ST6GALNAC5 | Human | maneb | multiple interactions | ISO | St6galnac5 (Mus musculus) | 6480464 | [Maneb co-treated with Paraquat] results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:36117858 | ST6GALNAC5 | Human | methotrexate | decreases expression | EXP | | 6480464 | Methotrexate results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:17379860 | ST6GALNAC5 | Human | methoxychlor | affects methylation | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Methoxychlor affects the methylation of ST6GALNAC5 gene | CTD | PMID:35440735 | ST6GALNAC5 | Human | methylmercury chloride | increases expression | EXP | | 6480464 | methylmercuric chloride results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:28001369 | ST6GALNAC5 | Human | N-methyl-4-phenylpyridinium | increases expression | EXP | | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:24810058 | ST6GALNAC5 | Human | nickel atom | decreases expression | EXP | | 6480464 | Nickel results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:25583101 | ST6GALNAC5 | Human | panobinostat | decreases expression | EXP | | 6480464 | panobinostat results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:26272509 | ST6GALNAC5 | Human | panobinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:27188386 | ST6GALNAC5 | Human | paraquat | multiple interactions | ISO | St6galnac5 (Mus musculus) | 6480464 | [Maneb co-treated with Paraquat] results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:36117858 | ST6GALNAC5 | Human | parathion | increases methylation | EXP | | 6480464 | Parathion results in increased methylation of ST6GALNAC5 promoter | CTD | PMID:22847954 | ST6GALNAC5 | Human | permethrin | increases expression | ISO | St6galnac5 (Rattus norvegicus) | 6480464 | Permethrin results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:19017407 | ST6GALNAC5 | Human | phenylmercury acetate | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:27188386 | ST6GALNAC5 | Human | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:22079256 | ST6GALNAC5 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:22079256 | ST6GALNAC5 | Human | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | EXP | | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:35811015 | ST6GALNAC5 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ST6GALNAC5 | Human | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:25351596 | ST6GALNAC5 | Human | sodium arsenite | affects methylation | EXP | | 6480464 | sodium arsenite affects the methylation of ST6GALNAC5 gene | CTD | PMID:28589171 | ST6GALNAC5 | Human | sunitinib | decreases expression | EXP | | 6480464 | Sunitinib results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:31533062 | ST6GALNAC5 | Human | terbufos | increases methylation | EXP | | 6480464 | terbufos results in increased methylation of ST6GALNAC5 promoter | CTD | PMID:22847954 | ST6GALNAC5 | Human | trichostatin A | decreases expression | EXP | | 6480464 | trichostatin A results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:24935251 and PMID:26272509 | ST6GALNAC5 | Human | trichostatin A | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:27188386 | ST6GALNAC5 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of ST6GALNAC5 mRNA | CTD | PMID:24935251 | ST6GALNAC5 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of ST6GALNAC5 mRNA | CTD | PMID:25979313 | ST6GALNAC5 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:23179753 more ... | ST6GALNAC5 | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ST6GALNAC5 mRNA | CTD | PMID:27188386 | |